Nephros' (NEPH) Hold (C) Rating Reaffirmed at Weiss Ratings

Key Points

• Nephros' stock has received a "hold (c)" rating from Weiss Ratings, while Maxim Group has raised its price target from $4.50 to $6.00, giving the company a "buy" rating.
• The company reported a net income of $0.02 EPS for the last quarter, exceeding analysts' expectations and achieving a revenue of $4.40 million.
• Institutional investors hold approximately 41.10% of Nephros' stock, with Geode Capital Management recently increasing its stake by 3.2%.

Nephros (NASDAQ:NEPH - Get Free Report)'s stock had its "hold (c)" rating reiterated by analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, Maxim Group lifted their price target on shares of Nephros from $4.50 to $6.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $5.50.

Nephros Stock Performance

Shares of NEPH opened at $5.16 on Wednesday. The business's 50-day moving average is $4.16 and its two-hundred day moving average is $3.28. The company has a market capitalization of $54.70 million, a P/E ratio of 43.00 and a beta of 1.32. Nephros has a fifty-two week low of $1.36 and a fifty-two week high of $5.97.

Nephros (NASDAQ:NEPH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.04. Nephros had a return on equity of 14.89% and a net margin of 7.95%.The firm had revenue of $4.40 million for the quarter, compared to analysts' expectations of $3.60 million.

Hedge Funds Weigh In On Nephros

A hedge fund recently raised its stake in Nephros stock. Geode Capital Management LLC grew its holdings in Nephros Inc. (NASDAQ:NEPH - Free Report) by 3.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,187 shares of the company's stock after acquiring an additional 2,898 shares during the period. Geode Capital Management LLC owned about 0.88% of Nephros worth $381,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 41.10% of the company's stock.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.